Ropes & Gray Advises Xeris Biopharma in Research Collaboration with Horizon Therapeutics

Ropes & Gray represented Xeris Biopharma in a research collaboration and choice arrangement with Horizon Therapeutics.

Less than the settlement announced on November 23, Xeris will use its proprietary formulation technology platform, XeriJect, to acquire an extremely-concentrated completely ready-to-use, subcutaneous injection of Horizon’s teprotumumab, and Horizon will have an selection to consider a business license below the Xeris know-how to exploit these kinds of re-formulated merchandise.

Teprotumumab is the first and only drugs accepted by the U.S. Foods and Drug Administration for the treatment method of Thyroid Eye Condition – a critical, progressive and potentially vision-threatening uncommon autoimmune condition. Xeris will receive an upfront payment, and may perhaps be entitled to acquire progress milestones, regulatory milestones, and income-centered milestones, as properly as royalties primarily based on foreseeable future revenue if the industrial license alternative is exercised. Fiscal conditions of the settlement have been not disclosed.

The Ropes & Grey crew was led by everyday living sciences partner Abigail Gregor and integrated tax partner Scott Pinarchick and strategic transactions associates Joe Muller and Adwoa Hinson.